We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Industry

Image: Proscia and Visiopharm share insights about future of digital pathology at USCAP 2022 (Photo courtesy of Visiopharm)

AI-Powered Pathology to Drive Insight in Cancer Diagnosis

Driven by a growing base of evidence on the economic and clinical benefits of adoption, leading laboratories are increasingly looking to adopt AI in routine practice to optimize operations and improve patient care. A key barrier to deriving the full value of AI is the lab’s ability to seamlessly integrate this diverse range of applications into routine operations. Now, a strategic partnership will deliver integrated AI-enabled solutions that aim to improve clinical decision making for cancer care. More...
25 Mar 2022
Image: Concentriq Dx digital pathology platform (Photo courtesy of Proscia)

Siemens Enters Digital Pathology Market with Proscia’s Concentriq Dx Platform

Siemens Healthineers (Erlangen, Germany) and Proscia (Philadelphia, PA, USA) have entered into a multi-year OEM agreement under which Siemens will expand its Enterprise Imaging offering towards the global digital pathology market using Proscia’s Concentriq Dx platform. With Proscia’s Concentriq Dx platform, Siemens is entering the digital pathology market to satiate the rampant demand and expand its Enterprise Imaging offering with industry-leading technology to realize the full value of digital pathology operations. More...
23 Mar 2022
Image: Bioperfectus has partnered with FIND to lift COVID-19 self-testing capacity in LMICs (Photo courtesy of Bioperfectus)

Bioperfectus Partners with FIND to Increase COVID-19 Self-Testing Capacity in Low and Middle-Income Countries

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China), a leading in-vitro diagnostics provider for infectious diseases, has partnered with FIND (Geneva, Switzerland), the global alliance for diagnostics, to accelerate the availability of affordable SARS-CoV-2 self-tests in low- and middle-income countries (LMICs). More...
15 Mar 2022
Image: Global blood collection devices market is projected to reach USD 7.8 billion by 2026 (Photo courtesy of Pexels)

Global Blood Collection Devices Market to Reach USD 7.8 Billion by 2026 Due to Increasing Incidence of Infectious Diseases

The global blood collection devices market is projected to register a CAGR of 6.0% from USD 5.7 billion in 2021 to USD 7.8 billion by 2026, driven primarily by the increasing incidence of infectious diseases, rising number of accidents & trauma cases, emergence of liquid biopsy tests, and demand for blood donations and blood components. However, the complexities of storage and shipping, and lack of skilled professionals are expected to restrain market growth during the forecast period. More...
14 Mar 2022
Image: Collaboration to evolve use of AI-powered pathology algorithms (Photo courtesy of Cleveland Clinic)

AI-Powered Pathology Can Radically Enhance Diagnostic Accuracy and Treatment Selection

A new collaborative effort will combine artificial intelligence (AI)-based platforms with clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics. More...
14 Mar 2022
Image: IHC staining controls (Photo courtesy of Boston Cell Standards)

Consortium for Analytic Standardization in Immunohistochemistry (IHC) Launched to Improve Patient IHC Test Accuracy

The Consortium for Analytic Standardization in Immunohistochemistry (CASI), launched by Boston Cell Standards (Boston, MA, USA; www.bostoncellstandards.com), is led by an international panel of pathologists and scientists, with a mission to integrate analytic reference standards into immunohistochemistry (IHC), a test format widely used in surgical pathology to evaluate cancers in tissue samples and determine correct treatment. More...
11 Mar 2022
Image: Lilly and Quanterix to jointly advance Alzheimer’s disease diagnosis (Photo courtesy of Quanterix)

Eli Lilly and Quanterix Collaborate to Advance Alzheimer's Blood-Based Biomarkers into Routine Clinical Use

Eli Lilly and Company (Lilly, Indianapolis, IN, USA) and Quanterix Corporation (Billerica, MA, USA) have entered into a collaboration to advance the diagnosis, monitoring and treatment of Alzheimer’s disease. As part of the collaboration, Quanterix will receive a non-exclusive, world-wide license to Lilly’s proprietary P-tau217 antibody technology for potential near-term use in research use only products and services, and future in vitro diagnostic applications. The parties have also entered into a collaboration agreement, which establishes a framework for future projects focused on the development of Simoa immunoassays. More...
09 Mar 2022
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Vaginitis Test
Allplex Vaginitis Screening Assay


LabMedica Industry News channel reports on mergers and takeovers, on cooperative agreements and on trends in the IVD industry worldwide.
Copyright © 2000-2025 Globetech Media. All rights reserved.